(Q37981969)

26 August 2017

Cutaneous T-cell lymphomas: a review of new discoveries and treatments (English)

1 reference

26 August 2017

Tara Bloom

1

1 reference

26 August 2017

Timothy M Kuzel

2

1 reference

26 August 2017

Christiane Querfeld

3

1 reference

26 August 2017

Joan Guitart

4

1 reference

26 August 2017

Steven T Rosen

5

1 reference

26 August 2017

1 March 2012

1 reference

Current Treatment Options in Oncology

26 August 2017

1 reference

26 August 2017

13

1 reference

26 August 2017

1

1 reference

26 August 2017

102-121

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-011-0179-8

26 August 2017

0 references

cites work

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

WHO-EORTC classification for cutaneous lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Notch1 expression in early lymphopoiesis influences B versus T lineage determination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Active Notch1 confers a transformed phenotype to primary human melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Tumor microenvironment and drug resistance in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Novel and highly recurrent chromosomal alterations in Sézary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Array-based comparative genomic hybridization in early-stage mycosis fungoides: recurrent deletion of tumor suppressor genes BCL7A, SMAC/DIABLO, and RHOF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Current and emerging treatment strategies for cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Phototherapy of mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Topical corticosteroids for mycosis fungoides. Experience in 79 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Cutaneous T cell lymphoma: update of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Bexarotene therapy for mycosis fungoides and Sézary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

The treatment of cutaneous T-cell lymphoma with photopheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

How cells respond to interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Expression of CD52 in peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

The CD52 antigen and development of the CAMPATH antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Effects on erythropoiesis of alemtuzumab-containing reduced intensity and standard conditioning regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Pralatrexate: an emerging new agent with activity in T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Gemcitabine in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Antibody-based therapeutics to watch in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Mycosis fongoïde transformé chez un enfant : traitement par transplantation médullaire allogénique avec effet « graft-versus-lymphoma »

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0179-8

Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality

21 January 2018

1 reference

12 December 2020

Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP

1 reference

12 December 2020

Ultraviolet radiation for treatment of cutaneous T-cell lymphoma

1 reference

12 December 2020

Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma

1 reference

12 December 2020

Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome

1 reference

12 December 2020

Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome

1 reference

12 December 2020

Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma

1 reference

12 December 2020

Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome

1 reference

12 December 2020

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype

1 reference

12 December 2020

Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma

1 reference

12 December 2020

Graft versus lymphoma effect after early relapse following reduced-intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides

1 reference

12 December 2020

Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center

1 reference

12 December 2020

Activity of Fludarabine Monophosphate in Patients With Advanced Mycosis Fungoides: A Southwest Oncology Group Study

1 reference

12 December 2020

Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma

1 reference

12 December 2020

Interferon alfa-2a in the treatment of cutaneous T cell lymphoma

1 reference

12 December 2020

Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution

1 reference

12 December 2020

Phase II trial of interferon-?-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma

1 reference

12 December 2020

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed

1 reference

12 December 2020

Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.

1 reference

12 December 2020

Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma

1 reference

12 December 2020

Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate

1 reference

12 December 2020

Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect

1 reference

12 December 2020

Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms

1 reference

12 December 2020

Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells

1 reference

12 December 2020

10.1007/S11864-011-0179-8

Identifiers

DOI

1 reference

26 August 2017

1 reference